QuantideX® NGS RNA Lung Cancer Kit
The QuantideX® NGS RNA Lung Cancer Kit* is a clinical research tool enabling the simultaneous assessment of fusions, exon skipping, and other expression targets frequently observed in non-small cell lung cancer (NSCLC). Leveraging our proprietary NGS-in-a-Box™ workflow and Sample-Aware™ bioinformatics quality control solutions, this kit offers a simple, sensitive, and reliable NGS assay for routine investigation of NSCLC samples.
Features & Benefits
The QuantideX NGS RNA Lung Cancer Kit offers a unique NGS-in-a-Box™ solution that provides unprecedented NGS workflow efficiency and high sensitivity at low input amounts from precious FFPE NSCLC samples.
Reduced ComplexityAssay incorporates sample-to-data solutions in a unique NGS-in-a-Box™ configuration
- Single assay for a broad range of important NSCLC fusion targets
- All-inclusive reagents from reverse transcription to NGS-ready library
- Fully integrated data analysis pipeline
Optimized WorkflowEfficient workflow leads to lower operational costs and reduced hands-on and total turnaround time*
- Reduced labor vs. current commercially available kits
- Improved turnaround time enables higher throughput
*Internal data on file.
Quality PerformanceHighly sensitive assay with integrated, Sample-Aware™ bioinformatics software and built-in quality checks to minimize erroneous results and sample failures
- Highly sensitive detection of RNA-based fusions
- Low input (~20ng) of RNA from FFPE
- Sample-Aware™ bioinformatics analysis and sample quality control
*For Research Use Only. Not for use in Diagnostic procedures.
Product Description
Relevant ContentA focus on only the most important lung cancer fusion genes, MET exon 14 skipping events, 3’/5′ imbalances and mRNA expression from multiple published data sources such as COSMIC, ClinicalTrials.gov, NCCN Guidelines, etc.
- 107 NSCLC-relevant fusions
- ALK, RET, ROS1, and NTRK1 3’/5’ imbalances
- MET exon 14 skipping events (e13/e14; e14/e15; e13/e15)
- 23 mRNA targets, plus 3 endogenous control transcripts
A Fully Integrated WorkflowA unique NGS-in-a-Box™ configuration offers a simplified and fully integrated NGS workflow with cGMP-manufactured reagents, components and controls ready to run right out of the box.
Includes:
- RT-PCR reagents
- A unique RNA Lung Cancer Sample QC kit (QuantideX qPCR RNA Assay (Lung))
- Gene-specific PCR primers and Master Mix reagents
- Barcodes for sample multiplexing
- Library purification and quantification reagents
- Integrated data analysis and reporting software (QuantideX NGS Reporter)
Rapid & EfficientAdopt and run NGS-based analysis with minimum investment of time and resources, regardless of NGS experience and infrastructure.
- Fully integrated workflow reduces complexity and ensures reliable reagent quality
- Push-button analysis & reporting makes bioinformatics easy and efficient, regardless of experience level
- Integrated kit reduces workflow time by over 50% than competing NGS panels
Performance DataQuantideX NGS Assay is capable of detecting fusions and splice variants down to 1:100 cells. (a) Admixture of MET exon 14 positive cell line in the background of wild-type cells, and (b) fusion, and (c) 3’/5’ imbalance status for an admixture of EML4-ALK positive FFPE in the background of a negative FFPE.
*For Research Use Only. Not for use in Diagnostic procedures.
QuantideX® NGS Reporter
Push-button analytics & reporting suite – Set-up-and-go workflow designed for easy installation and implementation, right out of the box.
Runs directly on lab desktop – Install locally on a Windows® desktop computer. No prior bioinformatics experience or large server environments required.
Comprehensive reporting – Full bioinformatics and reporting of variants (SNVs, SNPs, Indels, fusions), and standard QC metrics are automatically calculated.
Integrates QuantideX RNA/DNA QC Assay – Sample-Aware™ bioinformatics with integrated functional template copy number analysis dramatically reduces false-call rates.
Seamless updates offered with new panel designs & variant annotation – Software updates allow new panels to be adopted without re-investing in analytics when the Asuragen QuantideX NGS product line is adopted.
Contact us to request the QuantideX Reporter
Resources
Videos
Evaluation of an NGS Assay for Detecting RNA Fusions and Splicing Events in Lung Cancer
Next-Generation Sequencing Within Your Reach: Targeted RNA Sequencing to Help Guide NSCLC Patient Care
Posters
Accurate and Reproducible Detection of Fusions and Exon Skipping Events in NSCLC-Derived Samples Using A Comprehensive, Targeted RNA-Seq System Across Multiple LaboratoriesView full poster
Head-To-Head Comparison of Two Commercially Available Next-Generation Sequencing Technologies That Detect Gene Fusions In Non-Small Cell Lung CancerView full poster
A Simple and Versatile Next-Generation Sequencing Technology for Co-Detection of RNA Structural Variants and DNA Mutations in Lung Cancer View full poster
Ordering
Product Name | Number of Reactions | Catalog Number |
---|---|---|
QuantideX NGS RNA Lung Cancer Kit* | 48 | 49602 |
QuantideX NGS RNA Lung Cancer Kit* | 192 | 49603 |
T 1-877-777-1874; 512-681-5200 F 512-681-5202 E orders@asuragen.com
*For Research Use Only. Not for use in Diagnostic procedures.
QuantideX® NGS RNA Lung Cancer Kit
The QuantideX® NGS RNA Lung Cancer Kit* is a clinical research tool enabling the simultaneous assessment of fusions, exon skipping, and other expression targets frequently observed in non-small cell lung cancer (NSCLC). Leveraging our proprietary NGS-in-a-Box™ workflow and Sample-Aware™ bioinformatics quality control solutions, this kit offers a simple, sensitive, and reliable NGS assay for routine investigation of NSCLC samples.
Features & Benefits
The QuantideX NGS RNA Lung Cancer Kit offers a unique NGS-in-a-Box™ solution that provides unprecedented NGS workflow efficiency and high sensitivity at low input amounts from precious FFPE NSCLC samples.
Reduced ComplexityAssay incorporates sample-to-data solutions in a unique NGS-in-a-Box™ configuration
- Single assay for a broad range of important NSCLC fusion targets
- All-inclusive reagents from reverse transcription to NGS-ready library
- Fully integrated data analysis pipeline
Optimized WorkflowEfficient workflow leads to lower operational costs and reduced hands-on and total turnaround time*
- Reduced labor vs. current commercially available kits
- Improved turnaround time enables higher throughput
*Internal data on file.
Quality PerformanceHighly sensitive assay with integrated, Sample-Aware™ bioinformatics software and built-in quality checks to minimize erroneous results and sample failures
- Highly sensitive detection of RNA-based fusions
- Low input (~20ng) of RNA from FFPE
- Sample-Aware™ bioinformatics analysis and sample quality control
*For Research Use Only. Not for use in Diagnostic procedures.
Product Description
Relevant ContentA focus on only the most important lung cancer fusion genes, MET exon 14 skipping events, 3’/5′ imbalances and mRNA expression from multiple published data sources such as COSMIC, ClinicalTrials.gov, NCCN Guidelines, etc.
- 107 NSCLC-relevant fusions
- ALK, RET, ROS1, and NTRK1 3’/5’ imbalances
- MET exon 14 skipping events (e13/e14; e14/e15; e13/e15)
- 23 mRNA targets, plus 3 endogenous control transcripts
A Fully Integrated WorkflowA unique NGS-in-a-Box™ configuration offers a simplified and fully integrated NGS workflow with cGMP-manufactured reagents, components and controls ready to run right out of the box.
Includes:
- RT-PCR reagents
- A unique RNA Lung Cancer Sample QC kit (QuantideX qPCR RNA Assay (Lung))
- Gene-specific PCR primers and Master Mix reagents
- Barcodes for sample multiplexing
- Library purification and quantification reagents
- Integrated data analysis and reporting software (QuantideX NGS Reporter)
Rapid & EfficientAdopt and run NGS-based analysis with minimum investment of time and resources, regardless of NGS experience and infrastructure.
- Fully integrated workflow reduces complexity and ensures reliable reagent quality
- Push-button analysis & reporting makes bioinformatics easy and efficient, regardless of experience level
- Integrated kit reduces workflow time by over 50% than competing NGS panels
Performance DataQuantideX NGS Assay is capable of detecting fusions and splice variants down to 1:100 cells. (a) Admixture of MET exon 14 positive cell line in the background of wild-type cells, and (b) fusion, and (c) 3’/5’ imbalance status for an admixture of EML4-ALK positive FFPE in the background of a negative FFPE.
*For Research Use Only. Not for use in Diagnostic procedures.
QuantideX® NGS Reporter
Push-button analytics & reporting suite – Set-up-and-go workflow designed for easy installation and implementation, right out of the box.
Runs directly on lab desktop – Install locally on a Windows® desktop computer. No prior bioinformatics experience or large server environments required.
Comprehensive reporting – Full bioinformatics and reporting of variants (SNVs, SNPs, Indels, fusions), and standard QC metrics are automatically calculated.
Integrates QuantideX RNA/DNA QC Assay – Sample-Aware™ bioinformatics with integrated functional template copy number analysis dramatically reduces false-call rates.
Seamless updates offered with new panel designs & variant annotation – Software updates allow new panels to be adopted without re-investing in analytics when the Asuragen QuantideX NGS product line is adopted.
Contact us to request the QuantideX Reporter
Resources
Videos
Evaluation of an NGS Assay for Detecting RNA Fusions and Splicing Events in Lung Cancer
Next-Generation Sequencing Within Your Reach: Targeted RNA Sequencing to Help Guide NSCLC Patient Care
Posters
Accurate and Reproducible Detection of Fusions and Exon Skipping Events in NSCLC-Derived Samples Using A Comprehensive, Targeted RNA-Seq System Across Multiple LaboratoriesView full poster
Head-To-Head Comparison of Two Commercially Available Next-Generation Sequencing Technologies That Detect Gene Fusions In Non-Small Cell Lung CancerView full poster
A Simple and Versatile Next-Generation Sequencing Technology for Co-Detection of RNA Structural Variants and DNA Mutations in Lung Cancer View full poster
Ordering
Product Name | Number of Reactions | Catalog Number |
---|---|---|
QuantideX NGS RNA Lung Cancer Kit* | 48 | 49602 |
QuantideX NGS RNA Lung Cancer Kit* | 192 | 49603 |
T 1-877-777-1874; 1-512-681-5200 F 1-512-681-5202 E orders@asuragen.com
*For Research Use Only. Not for use in Diagnostic procedures.
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
)懂得一些道理或知识.
让世界充满爱不仅是付出,还可以是回报,回报你所关爱的人.
我记得有首歌曲,它的意思是爸爸妈妈辛苦了一天,回到家,帮他们拿拖鞋,帮他们倒杯茶,这是感
恩.老师批改作业累了,可以给他们捶捶背,当学习获得了一定的成功,老师会感到欣慰,这是感恩.当
同学遭遇困难时,你可以去用尽全力地安慰帮助他(她),使他(她)能够解决困难,克服困难,变得快
乐.这也是感恩.
为了帮助临床医师客观地了解NSAIDs,避开制药公司的导向以便更好地指导临床实践,本报请广州中山大学附属第一医院风湿免疫内科杨岫岩教授向读者介绍NSAIDs临床应用的一些问题。
NSAIDs的发展
从乙酰水杨酸(阿司匹林)应用至临床到现在,已经超过100个年头。1948年第一个非水杨酸类的NSAIDs保泰松问世后,抗炎镇痛药的种类迅速增加,如吲哚美辛、双氯芬酸、布洛芬、萘普生等,使NSAIDs“家族”迅速壮大。作为其“元老”的保泰松,虽然具有很强的抗炎镇痛作用,但潜在的严重副作用(再生障碍性贫血等)使其被淘汰。
1971年,环氧化酶(COX)理论解释了NSAIDs的作用机制。NSAIDs通过抑制COX,阻止花生四烯酸转变为前列腺素,后者既是炎症介质,又有生理功能。因此NSAIDs在抗炎镇痛的同时可引起胃肠道反应。20年后,研究者发现,COX存在不同的异构体,从而提出了COX异构体理论。认为COX存在两个异构体,一个是构建型的,称COX-1,以维持生理平衡为主;另一个是诱导型的称COX-2,主要参与炎症性前列腺素合成。
1994年,氟舒胺成为第一个被报道在实验室证实具有选择性COX-2抑制作用的NSAIDs,但在1996年III期临床试验总结时发现,该药具有肝毒性而未能获准上市。1995年Lancet上首先称萘丁美酮、美洛昔康、尼美舒利等为“选择性COX-2抑制剂”,虽然同年该期刊刊出几篇读者来信,对此提法提出争议,但是后来人们仍普遍接受这种提法。1999年,针对COX异构体理论研制的昔布类药物(塞来昔布和罗非昔布)上市,被称为“特异性COX-2抑制剂”。
虽然COX异构体理论尚需完善,但它的确是新型NSAIDs研制的一个突破口。除已经问世的昔布类药物外,新的昔布类Etoricoxib、parecoxib、valdecoxib也将投入临床。新研制的COX-2抑制剂不只限于昔布类,磺酰苯胺类也是研制新型COX-2抑制剂的方向,如氟舒胺、NS-398、HN-56249等。另外,针对COX和脂氧化酶(5-lipoxygenase